Thursday 27 April 2023
CXVascular.com
Join the community #CX2023
CX 2023 heralds new era of yearround education for the vascular community
DELEGATES CAN EXPECT another full programme of sessions and additional events on the third and final day of the 45th CX meeting. Stay tuned for the announcement of the winner of the Hurting Leg competition—a new feature of the 2023 programme—as well as a full-day venous and Hurting Leg workshop, audience polling in this morning’s thoracic session, and a Podium First in the CX Innovation Showcase later today. As the meeting draws to a close, the time has also come to look ahead at what is in store for 2024. Following this landmark anniversary symposium, headlined by the first-time BASIL-2 presentation on Tuesday, the CX Symposium is set
to return in 2024 with a controversies update. Next year, the meeting will take place in a new venue, the international ExCeL centre, with the aim of offering more space for the plenary programme, as well as larger exhibition and workshop spaces. The in-person and virtual CX 2023 event might be drawing to a close, but the education does not end here. All presentations, as well as CX materials from previous years, will be available to members of the online community at CXVascular.com after the event. Stay up to date with the latest updates in the vascular and endovascular world year-round with this new interactive platform, ahead of next year’s CX 2024 in-person and virtual event.
CX 2023 OVERVIEW
DAY THREE
Thoracic Aortic Consensus
Thoracic Aortic Thursday, 08:00–18:00 Kensington 1
CLTI & Hurting Leg Consensus
Chronic Limb-Threatening Ischaemia (CLTI) & Hurting Leg Thursday, 08:00–18:00 Kensington 2
2024
CX Innovation Showcase
CX Innovation Showcase Thursday, 08:00–18:00 Admiral
MISSED IT LIVE? AORTIC REPAIR
CX Podium First: Statins save lives after aortic repair regardless of dose
population due to cardiovascular disease,” Mani noted, adding that statin treatment is associated with improved survival in patients with ASCVD.
Statin treatment after aortic repair is associated with improved long-term survival, while dose does not matter. This was the key message from a Podium First presentation delivered by Kevin Mani (Uppsala, Sweden) during yesterday’s abdominal aortic session in Kensington 1. The CX audience showed their support for this conclusion, with 89% agreeing with the statement ‘Statins save Continued lives’ during discussion time. on page 4 Mani began by underlining the fact that abdominal aortic aneurysm (AAA) is a cardiovascular disease that shares risk factors with atherosclerotic cardiovascular disease (ASCVD). According to the American Heart Association (AHA), the presenter detailed, AAA is in fact classified as one of the ASCVDs. “AAA patients have a higher mortality than the general Continued on page 2
Kevin Mani
The presenter detailed that current European Society for Vascular Surgery (ESVS) guidelines on the management of abdominal aortoiliac artery aneurysms, published in 2019, suggest that patients with AAA should have blood pressure control, statins and antiplatelet therapy. “This is a class IIa recommendation with level B evidence,” the presenter specified, which he said indicates that “probably all patients” with AAA should have statin treatment. The AHA guidelines, Mani highlighted, split statin treatment into high dose and moderate to low dose. “The suggestion is that patients with ASCVD including those with AAA should have high-dose statin treatment,” the presenter shared with the Kensington 1 audience. “However,” he said, “the evidence for what dose should be given to AAA patients is non-existent, and the vascular surgical guidelines do not recommend a specific dose for AAA patients.” To address this gap in the literature, Mani
CATCH UP NOW WITH
ON-DEMAND
Scan here to view